[Beta-blockers. Value in cardiovascular diseases].
Feuring
M
M
Institut für Klinische Pharmakologie, Klinikum Mannheim, Ruprecht-Karls-Universität Heidelberg.
Schmidt
B M
BM
Christ
M
M
Wehling
M
M
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D015996:Survival Rate; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists
Beta-Blocker. Stellenwert bei kardiovaskulären Erkrankungen.